The Impact of the Genetic Polymorphism in DNA Repair Pathways on Increased Risk of Glioblastoma Multiforme in the Arab Jordanian Population: A Case–Control Study

References

• Curado M-P, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents. Vol. IX. IARC Press, International Agency for Research on Cancer; 2007.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Baldi I, Gruber A, Alioum A, et al. Descriptive epidemiology of CNS tumors in France: results from the gironde registry for the period 2000–2007. Neuro-Oncology. 2011;13(12):1370–1378. doi:10.1093/neuonc/nor120
   Web of Science ®Google Scholar
• Wöhrer A, Waldhör T, Heinzl H, et al. The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401. doi:10.1007/s11060-009-9938-9
   Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology. 2015;17(suppl4):iv1–iv62. doi:10.1093/neuonc/nov189
   PubMed Web of Science ®Google Scholar
• Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg. 1998;88(1):1–10. doi:10.3171/jns.1998.88.1.0001
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N Eng J Med. 2001;344(2):114–123. doi:10.1056/NEJM200101113440207
   PubMed Web of Science ®Google Scholar
• Miranda-Filho A, Piñeros M, Soerjomataram I, Deltour I, Bray F. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro-Oncology. 2016;now166. doi:10.1093/neuonc/now166
   Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Tabouret E, Nguyen AT, Dehais C, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 2016;132(4):625–634. doi:10.1007/s00401-016-1611-8
   Web of Science ®Google Scholar
• Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 Phase III trial. Neuro-Oncology. 2016;18(3):388–400. doi:10.1093/neuonc/nov182
   Web of Science ®Google Scholar
• Labussiere M, Di Stefano A, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 2014;111(10):2024–2032. doi:10.1038/bjc.2014.538
   PubMed Web of Science ®Google Scholar
• Network CGAR. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;2015(372):2481–2498.
   Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4
   PubMed Web of Science ®Google Scholar
• De Tayrac M, Saikali S, Aubry M, et al. Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas. PLoS One. 2013;8(9):e73332. doi:10.1371/journal.pone.0073332
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell 4th edn (New York: garland science). Ann Bot. 2002;91:401.
   Google Scholar
• Friedberg EC, Walker GC, Siede W, Wood RD. DNA Repair and Mutagenesis. American Society for Microbiology Press; 2005.
   Google Scholar
• Lu A-L, Li X, Gu Y, Wright PM, Chang D-Y. Repair of oxidative DNA damage. Cell Biochem Biophys. 2001;35(2):141–170. doi:10.1385/CBB:35:2:141
   Web of Science ®Google Scholar
• Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1(1):22. doi:10.1038/35094000
   PubMed Web of Science ®Google Scholar
• Aquilina G, Bignami M. Mismatch repair in correction of replication errors and processing of DNA damage. J Cell Physiol. 2001;187(2):145–154. doi:10.1002/jcp.1067
   Web of Science ®Google Scholar
• Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247. doi:10.1038/85798
   PubMed Web of Science ®Google Scholar
• David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447(7147):941. doi:10.1038/nature05978
   PubMed Web of Science ®Google Scholar
• Richard G-F, Kerrest A, Dujon B. Comparative genomics and molecular dynamics of DNA repeats in eukaryotes. Microbiol Mol Biol Rev. 2008;72(4):686–727.
   PubMed Web of Science ®Google Scholar
• Haber JE. Partners and pathways: repairing a double-strand break. Trends Genet. 2000;16(6):259–264. doi:10.1016/S0168-9525(00)02022-9
   Web of Science ®Google Scholar
• Ciccia A, Constantinou A, West SC. Identification and characterization of the human mus81-eme1 endonuclease. J Biol Chem. 2003;278(27):25172–25178. doi:10.1074/jbc.M302882200
   PubMed Web of Science ®Google Scholar
• Boddy MN, Gaillard P-HL, McDonald WH, Shanahan P, Yates JR, Russell P. Mus81-Eme1 are essential components of a Holliday junction resolvase. Cell. 2001;107(4):537–548. doi:10.1016/S0092-8674(01)00536-0
   PubMed Web of Science ®Google Scholar
• Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol. 2002;22(8):2556–2563. doi:10.1128/MCB.22.8.2556-2563.2002
   PubMed Web of Science ®Google Scholar
• Siciliano M, Bachinski L, Dolf G, Carrano A, Thompson L Chromosomal assignments of human DNA-repair genes that complement chinese-hamster ovary (cho) cell mutants. Paper presented at: CYTOGENETICS AND CELL GENETICS1987.
   Google Scholar
• Frederick GD, Amirkhan RH, Schultz RA, Friedberg EC. Structural and mutational analysis of the xeroderma pigmentosum group D (XPD) gene. Hum Mol Genet. 1994;3(10):1783–1788. doi:10.1093/hmg/3.10.1783
   Web of Science ®Google Scholar
• Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini AM, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20(2):184. doi:10.1038/2491
   PubMed Web of Science ®Google Scholar
• Wilson DM, Coleman MA, Adamson AW, Christensen M, Lamerdin JE, Carney JP. Hex1: a new human Rad2 nuclease family member with homology to yeast exonuclease 1. Nucleic Acids Res. 1998;26(16):3762–3768. doi:10.1093/nar/26.16.3762
   Web of Science ®Google Scholar
• Schmutte C, Marinescu RC, Sadoff MM, Guerrette S, Overhauser J, Fishel R. Human exonuclease I interacts with the mismatch repair protein hMSH2. Cancer Res. 1998;58(20):4537–4542.
   Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. doi:10.1126/science.7545954
   PubMed Web of Science ®Google Scholar
• Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000;14(8):927–939.
   PubMed Web of Science ®Google Scholar
• Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 2007;7(1):152. doi:10.1186/1471-2407-7-152
   Web of Science ®Google Scholar
• Maile EJ, Barnes I, Finlayson AE, Sayeed S, Nervous System AR. Intracranial tumour incidence by Ethnicity in England, 2001–2007: a descriptive epidemiological study. PLoS One. 2016;11(5):e0154347. doi:10.1371/journal.pone.0154347
   Web of Science ®Google Scholar
• Jacobs DI, Walsh KM, Wrensch M, et al. Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approach. Front Genet. 2012;3:203. doi:10.3389/fgene.2012.00203
   Google Scholar
• Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Prev Biomarkers. 2002;11(12):1513–1530.
   PubMed Web of Science ®Google Scholar
• Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291(5507):1284–1289. doi:10.1126/science.1056154
   PubMed Web of Science ®Google Scholar
• Chang JS, Yeh R-F, Wiencke JK, et al. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Prev Biomarkers. 2008;17(6):1368–1373. doi:10.1158/1055-9965.EPI-07-2830
   PubMed Web of Science ®Google Scholar
• Adel Fahmideh M, Schwartzbaum J, Frumento P, Feychting M. Association between DNA repair gene polymorphisms and risk of glioma: a systematic review and meta-analysis. Neuro-Oncology. 2014;16(6):807–814. doi:10.1093/neuonc/nou003
   PubMed Web of Science ®Google Scholar
• Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70(7):2789–2798. doi:10.1158/0008-5472.CAN-09-3541
   PubMed Web of Science ®Google Scholar
• Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13(20):2443–2449. doi:10.1093/hmg/ddh260
   PubMed Web of Science ®Google Scholar
• Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13(24):7413–7420. doi:10.1158/1078-0432.CCR-07-1083
   PubMed Web of Science ®Google Scholar
• Thrall M, Gallion H, Kryscio R, Kapali M, Armstrong DK, Deloia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a gynecologic oncology group study. Int J Gynecol Cancer. 2006;16(Suppl 1):166–171. doi:10.1136/ijgc-00009577-200602001-00026
   Google Scholar
• Kim H-T, Lee J-E, Shin E-S, et al. Effect of BRCA1 haplotype on survival of non–small-cell lung cancer patients treated with platinum-based chemotherapy. Journal of Clinical Oncology. 2008;26(36):5972–5979. doi:10.1200/JCO.2008.16.6496
   Web of Science ®Google Scholar
• Shim HJ, Yun JY, Hwang JE, et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 2010;101(5):1247–1254. doi:10.1111/j.1349-7006.2010.01514.x
   Web of Science ®Google Scholar
• Laroche-Clary A, Chaire V, Le Morvan V, et al. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. Br J Cancer. 2015;112(4):688–692. doi:10.1038/bjc.2014.624
   Web of Science ®Google Scholar
• Zhang X, Wei J, Zhou L, et al. A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013;34(10):2309–2313. doi:10.1093/carcin/bgt213
   Web of Science ®Google Scholar
• Alyahri N, Abdi S, Khan W, et al. Novel associations between brca1 variants C. 181 T> G (Rs28897672) and ovarian cancer risk in saudi females. J Med Biochem. 2019;38(1):13–21. doi:10.2478/jomb-2018-0037
   Web of Science ®Google Scholar
• Xu G-P, Zhao Q, Wang D, et al. The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis. Oncotarget. 2018;9(9):8681. doi:10.18632/oncotarget.24064
   Google Scholar